

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GENOR BIOPHARMA HOLDINGS LIMITED**

**嘉和生物藥業(開曼)控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6998)**

### **VOLUNTARY ANNOUNCEMENT UPDATES IN RELATION TO THE NDA APPROVAL OF GEPTANOLIMAB (GB226) FOR THE TREATMENT OF RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL)**

The announcement is made by Genor Biopharma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) announces that the Company has been notified by the China National Medical Products Administration that the New Product Application approval of Geptanolimab (GB226) as a treatment for relapsed/refractory peripheral T-cell lymphoma (PTCL) was not granted.

Save as disclosed above, the Company expects the development progress of other clinical trials or the Company’s other drug candidates would not be affected.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to develop, or ultimately market Geptanolimab (GB226) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Genor Biopharma Holdings Limited**  
**Dr. Guo Feng**  
*Chief Executive Officer and Chairman*

Hong Kong, 12 June 2023

*As at the date of this announcement, the Board comprises Dr. GUO Feng (Chief Executive Officer and Chairman) as an executive director; Dr. LYU Dong, Mr. CHEN Yu and Mr. LIU Yi as non-executive directors; Mr. ZHOU Honghao, Mr. FUNG Edwin and Mr. CHEN Wen as independent non-executive directors.*